Cargando…

In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism

Ataxin-2 (human gene symbol ATXN2) acts during stress responses, modulating mRNA translation and nutrient metabolism. Ataxin-2 knockout mice exhibit progressive obesity, dyslipidemia, and insulin resistance. Conversely, the progressive ATXN2 gain of function due to the fact of polyglutamine (polyQ)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sen, Nesli-Ece, Arsovic, Aleksandar, Meierhofer, David, Brodesser, Susanne, Oberschmidt, Carola, Canet-Pons, Júlia, Kaya, Zeynep-Ece, Halbach, Melanie-Vanessa, Gispert, Suzana, Sandhoff, Konrad, Auburger, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928749/
https://www.ncbi.nlm.nih.gov/pubmed/31766565
http://dx.doi.org/10.3390/ijms20235854
_version_ 1783482544262479872
author Sen, Nesli-Ece
Arsovic, Aleksandar
Meierhofer, David
Brodesser, Susanne
Oberschmidt, Carola
Canet-Pons, Júlia
Kaya, Zeynep-Ece
Halbach, Melanie-Vanessa
Gispert, Suzana
Sandhoff, Konrad
Auburger, Georg
author_facet Sen, Nesli-Ece
Arsovic, Aleksandar
Meierhofer, David
Brodesser, Susanne
Oberschmidt, Carola
Canet-Pons, Júlia
Kaya, Zeynep-Ece
Halbach, Melanie-Vanessa
Gispert, Suzana
Sandhoff, Konrad
Auburger, Georg
author_sort Sen, Nesli-Ece
collection PubMed
description Ataxin-2 (human gene symbol ATXN2) acts during stress responses, modulating mRNA translation and nutrient metabolism. Ataxin-2 knockout mice exhibit progressive obesity, dyslipidemia, and insulin resistance. Conversely, the progressive ATXN2 gain of function due to the fact of polyglutamine (polyQ) expansions leads to a dominantly inherited neurodegenerative process named spinocerebellar ataxia type 2 (SCA2) with early adipose tissue loss and late muscle atrophy. We tried to understand lipid dysregulation in a SCA2 patient brain and in an authentic mouse model. Thin layer chromatography of a patient cerebellum was compared to the lipid metabolome of Atxn2-CAG100-Knockin (KIN) mouse spinocerebellar tissue. The human pathology caused deficits of sulfatide, galactosylceramide, cholesterol, C22/24-sphingomyelin, and gangliosides GM1a/GD1b despite quite normal levels of C18-sphingomyelin. Cerebellum and spinal cord from the KIN mouse showed a consistent decrease of various ceramides with a significant elevation of sphingosine in the more severely affected spinal cord. Deficiency of C24/26-sphingomyelins contrasted with excess C18/20-sphingomyelin. Spinocerebellar expression profiling revealed consistent reductions of CERS protein isoforms, Sptlc2 and Smpd3, but upregulation of Cers2 mRNA, as prominent anomalies in the ceramide–sphingosine metabolism. Reduction of Asah2 mRNA correlated to deficient S1P levels. In addition, downregulations for the elongase Elovl1, Elovl4, Elovl5 mRNAs and ELOVL4 protein explain the deficit of very long-chain sphingomyelin. Reduced ASMase protein levels correlated to the accumulation of long-chain sphingomyelin. Overall, a deficit of myelin lipids was prominent in SCA2 nervous tissue at prefinal stage and not compensated by transcriptional adaptation of several metabolic enzymes. Myelination is controlled by mTORC1 signals; thus, our human and murine observations are in agreement with the known role of ATXN2 yeast, nematode, and mouse orthologs as mTORC1 inhibitors and autophagy promoters.
format Online
Article
Text
id pubmed-6928749
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69287492019-12-26 In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism Sen, Nesli-Ece Arsovic, Aleksandar Meierhofer, David Brodesser, Susanne Oberschmidt, Carola Canet-Pons, Júlia Kaya, Zeynep-Ece Halbach, Melanie-Vanessa Gispert, Suzana Sandhoff, Konrad Auburger, Georg Int J Mol Sci Article Ataxin-2 (human gene symbol ATXN2) acts during stress responses, modulating mRNA translation and nutrient metabolism. Ataxin-2 knockout mice exhibit progressive obesity, dyslipidemia, and insulin resistance. Conversely, the progressive ATXN2 gain of function due to the fact of polyglutamine (polyQ) expansions leads to a dominantly inherited neurodegenerative process named spinocerebellar ataxia type 2 (SCA2) with early adipose tissue loss and late muscle atrophy. We tried to understand lipid dysregulation in a SCA2 patient brain and in an authentic mouse model. Thin layer chromatography of a patient cerebellum was compared to the lipid metabolome of Atxn2-CAG100-Knockin (KIN) mouse spinocerebellar tissue. The human pathology caused deficits of sulfatide, galactosylceramide, cholesterol, C22/24-sphingomyelin, and gangliosides GM1a/GD1b despite quite normal levels of C18-sphingomyelin. Cerebellum and spinal cord from the KIN mouse showed a consistent decrease of various ceramides with a significant elevation of sphingosine in the more severely affected spinal cord. Deficiency of C24/26-sphingomyelins contrasted with excess C18/20-sphingomyelin. Spinocerebellar expression profiling revealed consistent reductions of CERS protein isoforms, Sptlc2 and Smpd3, but upregulation of Cers2 mRNA, as prominent anomalies in the ceramide–sphingosine metabolism. Reduction of Asah2 mRNA correlated to deficient S1P levels. In addition, downregulations for the elongase Elovl1, Elovl4, Elovl5 mRNAs and ELOVL4 protein explain the deficit of very long-chain sphingomyelin. Reduced ASMase protein levels correlated to the accumulation of long-chain sphingomyelin. Overall, a deficit of myelin lipids was prominent in SCA2 nervous tissue at prefinal stage and not compensated by transcriptional adaptation of several metabolic enzymes. Myelination is controlled by mTORC1 signals; thus, our human and murine observations are in agreement with the known role of ATXN2 yeast, nematode, and mouse orthologs as mTORC1 inhibitors and autophagy promoters. MDPI 2019-11-21 /pmc/articles/PMC6928749/ /pubmed/31766565 http://dx.doi.org/10.3390/ijms20235854 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sen, Nesli-Ece
Arsovic, Aleksandar
Meierhofer, David
Brodesser, Susanne
Oberschmidt, Carola
Canet-Pons, Júlia
Kaya, Zeynep-Ece
Halbach, Melanie-Vanessa
Gispert, Suzana
Sandhoff, Konrad
Auburger, Georg
In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism
title In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism
title_full In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism
title_fullStr In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism
title_full_unstemmed In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism
title_short In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism
title_sort in human and mouse spino-cerebellar tissue, ataxin-2 expansion affects ceramide-sphingomyelin metabolism
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928749/
https://www.ncbi.nlm.nih.gov/pubmed/31766565
http://dx.doi.org/10.3390/ijms20235854
work_keys_str_mv AT sennesliece inhumanandmousespinocerebellartissueataxin2expansionaffectsceramidesphingomyelinmetabolism
AT arsovicaleksandar inhumanandmousespinocerebellartissueataxin2expansionaffectsceramidesphingomyelinmetabolism
AT meierhoferdavid inhumanandmousespinocerebellartissueataxin2expansionaffectsceramidesphingomyelinmetabolism
AT brodessersusanne inhumanandmousespinocerebellartissueataxin2expansionaffectsceramidesphingomyelinmetabolism
AT oberschmidtcarola inhumanandmousespinocerebellartissueataxin2expansionaffectsceramidesphingomyelinmetabolism
AT canetponsjulia inhumanandmousespinocerebellartissueataxin2expansionaffectsceramidesphingomyelinmetabolism
AT kayazeynepece inhumanandmousespinocerebellartissueataxin2expansionaffectsceramidesphingomyelinmetabolism
AT halbachmelanievanessa inhumanandmousespinocerebellartissueataxin2expansionaffectsceramidesphingomyelinmetabolism
AT gispertsuzana inhumanandmousespinocerebellartissueataxin2expansionaffectsceramidesphingomyelinmetabolism
AT sandhoffkonrad inhumanandmousespinocerebellartissueataxin2expansionaffectsceramidesphingomyelinmetabolism
AT auburgergeorg inhumanandmousespinocerebellartissueataxin2expansionaffectsceramidesphingomyelinmetabolism